BridgeMD
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab or Nivolumab plus Ipilimumab in Patients with Advanced Cancers
EU CTIS ID: 2023-509061-20-00
What this study is testing
1.To find out if BMS-986253 is safe and determine the best dose of BMS-986253 to give patients in future studies when used with other anti-cancer drugs in advanced solid tumors. 2.To find out how well the treatment of other anti-cancer drugs in combination with BMS-986253 work at treating advanced solid tumors, as compared to when paired with a placebo.
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- At least 1 lesion accessible for biopsy
- Eastern Cooperative Oncology Group Performance Status of 0 or 1
- Non-small cell lung carcinoma (only Part 1A and Part 1 Cohorts 1B1 through 1B5 [enrolled through revised Protocol 03]. Participants with NSCLC will not be allowed in Parts 1B6, 1B7 and 1C as per protocol Amendment 04).
You likely can't join if
- Participants with brain tumors as the only cancer site
- Participants with autoimmune disease, history of severe side effects from previous anti-cancer therapy, uncontrolled cardiovascular disease, chronic liver inflammation, and other specified conditions.
- Prior systemic cancer-directed treatments or investigational modalities ≤ 5 half- lives or 4 weeks prior to starting study treatment, whichever is shorter.
- Active infections requiring systemic therapythat is not associated with the underlying tumor.
- Participantson chronic systemic immunosuppressive therapy or corticosteroids.
- Pregnancy and Nursing subjects
The study team makes the final eligibility decision.
Where it's taking place
- Canada
- United States
- Switzerland
- Australia
- United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Canada; United States; Switzerland; Australia; United Kingdom. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.